NCT03885934View on ClinicalTrials.gov

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)

PHASE3CompletedINTERVENTIONAL
Enrollment

606

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

December 9, 2020

Study Completion Date

December 9, 2020

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

V114

V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration

BIOLOGICAL

Prevnar 13®

Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.

Trial Locations (26)

10330

Chulalongkorn University ( Site 0601), Bangkok

10400

Vaccine Trial Center Faculty of Tropical Medicine ( Site 0603), Bangkok

10700

Siriraj Hospital ( Site 0600), Bangkok

20520

Tampereen yliopisto Turun rokotetutkimusklinikka ( Site 0002), Turku

28100

Tampereen yliopisto Porin rokotetutkimusklinikka ( Site 0008), Pori

33100

Tampereen yliopisto - Tampereen rokotetutkimusklinikka ( Site 0001), Tampere

40002

Srinagarind Hospital ( Site 0602), Khonkaen

59100

University Malaya Medical Centre ( Site 0901), Kuala Lumpur

60100

Seinajoki Vaccine Research Center ( Site 0010), Seinäjoki

67100

Tampereen yliopisto Kokkolan rokotetutkimusklinikka ( Site 0009), Kokkola

88996

Sabah Womens & Childrens Hospital ( Site 0902), Kota Kinabalu

90220

Tampereen yliopisto Oulun rokotetutkimusklinikka ( Site 0004), Oulu

119333

Central Clinical Hospital of Russian Academy Science ( Site 0317), Moscow

193312

Children s City Polyclinic No. 45 of the Nevsky District ( Site 0312), Saint Petersburg

197022

Research Institute of Children Infections ( Site 0301), Saint Petersburg

620028

MAI Childrens City Clinical Hospital 11 ( Site 0305), Yekaterinburg

02230

Tampereen yliopisto Espoon rokotetutkimusklinikka ( Site 0007), Espoo

00100

Tampereen yliopisto Etelä-Helsingin rokotetutkimusklinikka ( Site 0005), Helsinki

00930

Tampereen yliopisto Ita-Helsingin rokotetutkimusklinikka ( Site 0006), Helsinki

04400

Tampereen yliopisto Järvenpään rokotetutkimusklinikka ( Site 0003), Järvenpää

85-079

Przychodnia Vitamed Gaaj i Cichomski Spolka Jawna ( Site 0212), Bydgoszcz

85-796

Centrum Medyczne Pratia Bydgoszcz ( Site 0210), Bydgoszcz

61-709

Spec Zesp Opieki Zdrowotnej nad Matka i Dzieckiem w Poznaniu ( Site 0213), Poznan

41-103

NZ Lecznictwa Ambulatoryjnego - Michalkowice - Jarosz i Partnerzy ( Site 0211), Siemianowice Śląskie

50-368

Uniwersytecki Szpital Kliniczny ( Site 0207), Wroclaw

05-092

SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 0209), Łomianki

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03885934 - Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) | Biotech Hunter | Biotech Hunter